Gain of 1q is associated with inferior event‐free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|21|3887-3894

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.21, 2013-11, pp. : 3887-3894

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti‐angiogenic therapy: A report from the children's oncology group phase I consortium

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 1, 2015-01 ,pp. : 45-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 4, 2018-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy—a report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 49, Iss. 7, 2007-12 ,pp. : 894-900

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 759-765

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 3, 2015-03 ,pp. : 440-444

John Wiley & Sons Inc

Access to resources Recommend Favorite